30,000 Shares in Nurix Therapeutics, Inc. $NRIX Purchased by Maven Securities LTD

Maven Securities LTD bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 30,000 shares of the company’s stock, valued at approximately $569,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Kennedy Capital Management LLC lifted its holdings in shares of Nurix Therapeutics by 5.9% during the 4th quarter. Kennedy Capital Management LLC now owns 261,204 shares of the company’s stock worth $4,955,000 after acquiring an additional 14,461 shares during the period. Eventide Asset Management LLC bought a new stake in shares of Nurix Therapeutics during the 4th quarter worth approximately $24,621,000. Barclays PLC lifted its holdings in shares of Nurix Therapeutics by 4.7% during the 4th quarter. Barclays PLC now owns 256,684 shares of the company’s stock worth $4,869,000 after acquiring an additional 11,589 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Nurix Therapeutics by 579.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 172,364 shares of the company’s stock worth $3,277,000 after acquiring an additional 147,012 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of Nurix Therapeutics during the 4th quarter worth approximately $1,420,000.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. BTIG Research upped their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Jefferies Financial Group upped their price target on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, June 8th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a report on Wednesday, June 10th. Needham & Company LLC reiterated a “buy” rating and set a $34.00 price objective on shares of Nurix Therapeutics in a research report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.14.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 14,055 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the sale, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. This represents a 27.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 3,214 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $16.65, for a total transaction of $53,513.10. Following the completion of the sale, the insider directly owned 120,399 shares in the company, valued at approximately $2,004,643.35. This represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 19,657 shares of company stock worth $326,586. Insiders own 6.70% of the company’s stock.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $17.04 on Tuesday. The firm’s fifty day moving average is $16.45 and its 200-day moving average is $16.91. Nurix Therapeutics, Inc. has a 52 week low of $8.19 and a 52 week high of $22.50. The firm has a market cap of $1.76 billion, a P/E ratio of -5.39 and a beta of 1.86.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. The firm had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million. As a group, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.88 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.